JP2016508026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508026A5 JP2016508026A5 JP2015542310A JP2015542310A JP2016508026A5 JP 2016508026 A5 JP2016508026 A5 JP 2016508026A5 JP 2015542310 A JP2015542310 A JP 2015542310A JP 2015542310 A JP2015542310 A JP 2015542310A JP 2016508026 A5 JP2016508026 A5 JP 2016508026A5
- Authority
- JP
- Japan
- Prior art keywords
- pca
- category
- composite value
- biomarker
- snppc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251310-7 | 2012-11-20 | ||
| SE1251310 | 2012-11-20 | ||
| SE1350602 | 2013-05-16 | ||
| SE1350602-7 | 2013-05-16 | ||
| PCT/EP2013/074270 WO2014079874A1 (en) | 2012-11-20 | 2013-11-20 | Prognostic method for individuals with prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016508026A JP2016508026A (ja) | 2016-03-17 |
| JP2016508026A5 true JP2016508026A5 (enExample) | 2017-01-05 |
Family
ID=49713059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542310A Pending JP2016508026A (ja) | 2012-11-20 | 2013-11-20 | 前立腺癌を有する個体の予後診断方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10428385B2 (enExample) |
| EP (1) | EP2922970B1 (enExample) |
| JP (1) | JP2016508026A (enExample) |
| AU (1) | AU2013349721B2 (enExample) |
| CA (1) | CA2891394C (enExample) |
| ES (1) | ES2694409T3 (enExample) |
| RU (1) | RU2669809C2 (enExample) |
| WO (1) | WO2014079874A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6308954B2 (ja) | 2012-03-05 | 2018-04-11 | オサケユキテュア・アークティック・パートナーズ・アクチボラゲットＯｙ Ａｒｃｔｉｃ Ｐａｒｔｎｅｒｓ Ａｂ | 前立腺癌のリスク及び前立腺容積を予測する方法及び装置 |
| MY182773A (en) | 2012-11-20 | 2021-02-05 | Phadia Ab | Method for indicating a presence or non-presence of aggressive prostate cancer |
| CA2940445C (en) * | 2014-03-11 | 2021-11-30 | Phadia Ab | Method for detecting a solid tumor cancer |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| CN114740202A (zh) | 2014-03-28 | 2022-07-12 | 欧普科诊断有限责任公司 | 与前列腺癌的诊断有关的组合物和方法 |
| EP3253800B1 (en) | 2015-03-27 | 2021-03-03 | Opko Diagnostics, LLC | Prostate antigen standards and uses thereof |
| CA2982262A1 (en) | 2015-04-29 | 2016-11-03 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| JP6570929B2 (ja) * | 2015-09-08 | 2019-09-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | 特性推定モデル生成装置および方法、解析対象の特性推定装置および方法 |
| US20190345565A1 (en) * | 2017-02-01 | 2019-11-14 | Phadia Ab | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
| CN111712878A (zh) * | 2018-01-22 | 2020-09-25 | 法迪亚股份公司 | 用于协调分析结果的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP2522743A3 (en) | 2007-02-07 | 2013-08-07 | Decode Genetics EHF. | Genetic variants contributing to risk of prostate cancer |
| EP2611943B1 (en) | 2010-09-03 | 2017-01-04 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) * | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| EP2850432A2 (en) | 2012-05-16 | 2015-03-25 | Phadia AB | Method for indicating the presence or non-presence of prostate cancer |
| MY182773A (en) | 2012-11-20 | 2021-02-05 | Phadia Ab | Method for indicating a presence or non-presence of aggressive prostate cancer |
-
2013
- 2013-11-20 RU RU2015124008A patent/RU2669809C2/ru active
- 2013-11-20 JP JP2015542310A patent/JP2016508026A/ja active Pending
- 2013-11-20 ES ES13799501.5T patent/ES2694409T3/es active Active
- 2013-11-20 EP EP13799501.5A patent/EP2922970B1/en active Active
- 2013-11-20 CA CA2891394A patent/CA2891394C/en active Active
- 2013-11-20 AU AU2013349721A patent/AU2013349721B2/en active Active
- 2013-11-20 US US14/443,974 patent/US10428385B2/en active Active
- 2013-11-20 WO PCT/EP2013/074270 patent/WO2014079874A1/en not_active Ceased
-
2019
- 2019-09-19 US US16/575,940 patent/US20200010912A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503301A5 (enExample) | ||
| AU2021232712B2 (en) | Method for detecting a solid tumor cancer | |
| Takeuchi et al. | The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer | |
| Okamura et al. | Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma | |
| Aly et al. | Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study | |
| Prensner et al. | RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 | |
| Bonne et al. | Salivary biomarker development using genomic, proteomic and metabolomic approaches | |
| JP2019049559A (ja) | 侵攻性前立腺癌の存在または不存在を判定する方法 | |
| Martuszewski et al. | Donor-derived cell-free DNA in kidney transplantation as a potential rejection biomarker: a systematic literature review | |
| Wang et al. | Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma | |
| JP2017508970A5 (enExample) | ||
| JP2015524052A (ja) | 前立腺癌の存在または不存在の提示方法 | |
| ES2694409T3 (es) | Método de pronóstico para individuos con cáncer de próstata | |
| Irvine et al. | Multiplex serum protein analysis identifies novel biomarkers of advanced fibrosis in patients with chronic liver disease with the potential to improve diagnostic accuracy of established biomarkers | |
| Zhou et al. | Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection | |
| CN107657149B (zh) | 用于预测肝癌患者预后的系统 | |
| JP2016526167A5 (enExample) | ||
| Wu et al. | The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC | |
| Yasuda et al. | Preoperative predictors of very early recurrence in patients with hepatocellular carcinoma beyond the Milan criteria | |
| Liang et al. | Prospective evaluation of operating characteristics of prostate cancer detection biomarkers | |
| FI3577237T3 (fi) | Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia | |
| Yang et al. | Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study | |
| US20250210192A1 (en) | Methods for disease detection | |
| Hu et al. | Development of a redox-related prognostic signature for predicting biochemical-recurrence-free survival of prostate cancer | |
| Marconi et al. | Post partial nephrectomy surveillance imaging: an evidence-based approach |